Realization of a cascade treatment algorithm for glaucoma in St. Petersburg
DOI: 10.32364/2311-7729-2021-21-3-123-128
A.V. Antonova1, V.P. Nikolaenko1,2, V.V. Brzheskiy3
1City Multidisciplinary Hospital No. 2, St. Petersburg, Russian Federation
2St. Petersburg State University, St. Petersburg, Russian Federation
3St. Petersburg State Pediatric Medical University, St. Petersburg, Russian Federation
Aim: to analyze the duration and regimen of topical treatment and the pattern of prior laser and surgical procedures in patients with glaucoma who were admitted to the hospital for IOP-lowering interventions.
Patients and Methods: this study included 500 consecutively enrolled patients who underwent surgery for uncontrolled glaucoma in 2016–2020 and were followed up for 6–24 months. Disease history, cumulative "preservative" load, clinical examinations, and surgical outcomes were assessed.
Results: preoperatively, most patients received the maximum medical therapy (i.e., three agents in two bottles). Simultaneous use of all four major classes of IOP-lowering medications occurred in 10% of patients only. Two-third of patients required surgical interventions to reduce IOP after a 6-year medical therapy. By the time of admission, 60% of patients were diagnosed with advanced or end-stage glaucoma. Prior laser or surgical procedures to reduce IOP were performed only in 142 patients and 52 patients, respectively. Treatment adherence was lower in men compared to women, irrespective of its stage.
Conclusion: most patients received adequate medical therapy. However, in general, surgery was performed too late. It gives the impression that the efficacy of therapeutic and laser stages of cascade glaucoma treatment is no more than five years. In addition to the obvious drawbacks of a laissez-faire strategy (irreversible vision loss), the risk of surgical failure significantly increases. Long-term (at least 3-year) therapy using (non)fixed-dose combinations of agents containing preservatives is the major modifiable risk factor for early filtration loss. Preservative-free prostaglandin analogues improve treatment tolerability, adherence to treatment, and chances for success of IOP-lowering surgery. The authors’ results demonstrate that gender differences should be considered when planning treatment and follow-up visits.
Keywords: glaucoma, IOP-lowering therapy, glaucoma surgery, ocular surface, preservatives, benzalkonium chloride.
For citation: Antonova A.V., Nikolaenko V.P., Brzheskiy V.V. Realization of a cascade treatment algorithm for glaucoma in St. Petersburg. Russian Journal of Clinical Ophthalmology. 2021;21(3):123–128 (in Russ.). DOI: 10.32364/2311-7729-2021-21-3-123-128.
About the authors:
1Anastasiya V. Antonova — ophthalmologist; ORCID iD 0000-0002-2639-2765.
1,2Vadim P. Nikolaenko — Dr. Sc. (Med.), professor of the Department of ENT Diseases & Ophthalmology, Deputy Head Doctor for Ophthalmology; ORCID iD 0000- 0002-6393-1289.
3Vladimir. V. Brzheskiy — Dr. Sc. (Med.), Professor, Head of the Department of Ophthalmology; ORCID iD 0000-0001-7361-0270.
1City Multidisciplinary Hospital No. 2, 5, Uchebnyy lane, St. Petersburg, 194354, Russian Federation.
2St. Petersburg State University, 7/9, Universitetskaya emb., St. Petersburg, 199106, Russian Federation.
3St. Petersburg State Pediatric Medical University, 2, Litovskaya str., St. Petersburg, 194100, Russian Federation.
Contact information: Anastasiya V. Antonova, e-mail: dr.antonova.av@gmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 30.07.2021.
2. Куроедов А.В., Брежнев А.Ю., Ловпаче Д.Н. и др. Целесообразность применения дифференцированных («ступенчатых») стартовых подходов к лечению больных с разными стадиями глаукомы. Национальный журнал Глаукома. 2018;17(4):27-54. [Kuroyedov A.V., Brezhnev A.Yu., Lovpache J.N. et al. The feasibility of adopting «stepwise» initial approaches in treatment of patients with different stages of glaucoma. National Journal glaucoma. 2018;17(4):27-54 (in Russ.)]. DOI: 10.25700/NJG.2018.04.03.
3. Куроедов А.В., Криницына Е.А., Сергеева В.М., Городничий В.В. Изменение структуры клинико-эпидемиологических показателей первичной открытоугольной глаукомы за 10 лет у пациентов, поступающих на оперативное лечение. Клиническая офтальмология. 2017;18(4):205-212. [Kuroyedov A.V., Krinitsyna E.A., Sergeeva V.M., Gorodnichiy V.V. Changes in the structure of clinical and epidemiological characteristics of primary open-angle glaucoma over 10 years in patients coming to surgical treatment. Russian Journal of Clinical ophthalmology. 2017;18(4):205-212 (in Russ.)]. DOI: 10.21689/2311-7729-2017-17-4-205-212.
4. Бржеский В.В. Глаукома и синдром «сухого глаза». М.: БОРГЕС; 2018. [Brzheskij V.V. Glaucoma and dry eye syndrome. М.: BORGES; 2018 (in Russ.)].
5. Gupta P.K., Drinkwater O.J., van Dusen K.W. et al. Prevalence of ocular surface dysfunction in patients presenting for cataract surgery evaluation. J. Cataract Refract. Surg. 2018;44(9):1090–1096. DOI: 10.1016/j.jcrs.2018.06.026.
6. Pérez-Bartolomé F., Martínez-de-la-Casa J.M., Arriola-Villalobos P. et al. Ocular surface disease in patients under topical treatment for glaucoma. Eur. J. Ophthalmol. 2017;27(6):694–704. DOI: 10.5301/ejo.5000977.
7. Николаенко В.П., Астахов Ю.С. Использование политетрафторэтиленовых эксплантатов в ходе гипотензивных операций. Техника и результаты лечения первичной терминальной глаукомы. Клинич. офтальмология. 2005;6(2):74–78. [Nikolajenko V.P., Astakhov Yu.S. Use of polytetrafluoroethylene setons in glaucoma surgery. Technique and results of surgical treatment of primary end-stage open-angle glaucoma. Russian Journal of Clinical Ophthalmology. 2005;6(2):74–78 (in Russ.)].
8. Астахов Ю.С., Николаенко В.П., Дьяков В.Е. Использование политетрафторэтиленовых имплантатов в офтальмохирургии. М.: Фолиант; 2007. [Astakhov Ju.S., Nikolaenko V.P., D’jakov V.E. The use of polytetrafluoroethylene implants in ophthalmic surgery; 2007 (in Russ.)].
9. Heuer D.K., Lloyd M.A., Abrams D.A. et al. Which is better? One or two? A randomized clinical trial of single-plate versus double-plate Molteno implantation for glaucomas in aphakia and pseudophakia. Ophthalmology. 1992;99(10):1512–1519. DOI: 10.1016/s0161-6420(92)31772-5.
10. Lloyd M.A., Sedlak T., Heuer D.K. et al. Clinical experience with the single-plate Molteno implant in complicated glaucomas. Update of a pilot study. Ophthalmology. 1992;99(5):679–687. DOI: 10.1016/s0161-6420(92)31910-4.
11. Lloyd M.A., Baerveldt G., Heuer D.K. et al. Initial clinical experience with the Baerveldt implant in complicated glaucomas. Ophthalmology. 1994;101(4):640–650. DOI: 10.1016/s0161-6420(94)31283-8.
12. Sidoti P.A., Dunphy T.R., Baerveldt G. et al. Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma. Ophthalmology. 1995;102(7):1107–1118. DOI: 10.1016/s0161-6420(95)30904-9.
13. Mills R.P., Reynolds A., Emond M.J. et al. Long-term survival of Molteno glaucoma drainage devices. Ophthalmology. 1996;103(2):299–305. DOI: 10.1016/s0161-6420(96)30700-8.
14. Minckler D.S., Heuer D.K., Hasty B. et al. Clinical experience with the single-plate Molteno implant in complicated glaucoma. Ophthalmology. 1988;95(9):1181–1188. DOI: 10.1016/s0161-6420(88)33029-0.
15. Broadway D.C., Chang L.P. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J. Glaucoma. 2001;10:237–249. DOI: 10.1097/00061198-200106000-00017.
16. Stapleton F., Alves M., Bunya V.Y. et al. TFOS DEWS II — Epidemiology report. Ocul Surf. 2017;15(3):334–365.
17. Salim S., Shields M.B. Glaucoma and systemic diseases. Surv. Ophthalmol. 2010;55(1):64–77. DOI: 10.1016/j.survophthal.2009.03.006.
18. Zhang X., Zhao L., Deng S. et al. Dry eye syndrome in patients with diabetes mellitus: prevalence, etiology, and clinical characteristics. J. Ophthalmol. 2016;2016:8201053. DOI: 10.1155/2016/8201053.
19. Ferrero A., Alassane S., Binquet C. et al. Dry eye disease in the elderly in a French population-based study (the Montrachet study: Maculopathy, Optic Nerve, nuTRition, neurovAsCular and HEarT diseases): Prevalence and associated factors. Ocul. Surf. 2018;16(1):112–119. DOI: 10.1016/j.jtos.2017.09.008.
20. Millán A., Viso E., Gude F. et al. Incidence and risk factors of dry eye in a Spanish adult population: 11-year follow-up from the Salnes Eye Study. Cornea. 2018;37(12):1527–1534. DOI: 10.1097/ ICO. 0000000000001713.
21. Dana R., Bradley J.L., Guerin A. et al. Comorbidities and prescribed medications in patients with or without dry eye disease: A population-based study. Am. J. Ophthalmol. 2019;198:181–192. DOI: 10.1016/j.ajo.2018.10.001.
22. Yoo T.K., Oh E. Diabetes mellitus is associated with dry eye syndrome: a meta-analysis. Int. Ophthalmol. 2019;39(11):2611–2620. DOI: 10.1007/ s10792-019-01110-y.
23. Дедов И.И., Шестакова М.В., Викулова О.К. и др Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. Сахарный диабет. 2018;21(3):144–159. DOI: 10.14341/DM9686. [Dedov I.I., Shestakova M.V., Vikulova O.K. et al. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017. Diabetes mellitus. 2018;21(3):144-159 (in Russ.)].
24. Арутюнов Г.П., Баранова Е.И., Барбараш О.Л. и др Артериальная гипертензия у взрослых. Клинические рекомендации. 2020. Российский кардиологический журнал. 2020;25(3):3786. DOI: 10.15829/1560-4071-2020-3-3786. [Arutyunov G.P., Baranova E.I., Barbarash O.L. et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786 (in Russ.)].
25. Dave A., Bali S.J., Sharma R. et al. Prevalence of diabetes mellitus and hypertension among Indian glaucoma patients and evaluation of systemic therapy. Int. Ophthalmol. 2013;33(5):527–532. DOI: 10.1007/s10792-013-9737-3.
26. Zhao Y., Fu J.L., Li Y.L. et al. Epidemiology and clinical characteristics of patients with glaucoma: An analysis of hospital data between 2003 and 2012. Indian J. Ophthalmol. 2015;63(11):825–831. DOI: 10.4103/0301-4738.171963.
27. Kawashima M., Yamada M., Shigeyasu C. et al. Association of systemic comorbidities with Dry Eye Disease. J. Clin. Med. 2020;9(7):2040. DOI: 10.3390/jcm9072040.
28. Макогон С.И., Макогон А.С. Анализ причин низкой приверженности лечению у пациентов с первичной открытоугольной глаукомой. Вестник современной клинической медицины. 2015;8(6):52–57. [Makogon S.I., Makogon A.S. Analysis of the causes of low adherence to treatment in patients of primary open angle glaucoma. The Bulletin of Contemporary Clinical Medicine. 2015;8(6):52–57 (in Russ.)].
29. Jones J.P., Fong D.S., Fang E.N. et al. Characterization of glaucoma medication adherence in Kaiser Permanente Southern California. Glaucoma. 2016;25(1):22–26. DOI: 10.1097/IJG.0000000000000205.
30. Broadway D.C., Grierson I., O’Brien C. et al. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch. Ophthalmol. 1994;112(11):1437–1445. DOI: 10.1001/archopht.1994.01090230051020.
31. Garcia-Feijoo J., Sampaolesi J.R. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin. Ophthalmol. 2012;6:441–446. DOI: 10.2147/OPTH.S29158.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать